ersonal use only
Institutional Investor Presentation
10 November 2021 ASX:RHY
A transformative and predictive cancer diagnostics technology company
ersonal use only
Disclaimer
This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.
This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Rhythm makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. Rhythm and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.
This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.
This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of Rhythm. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Rhythm or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.
2
Introduction
onlyRhythm's initial product, ColoSTAT® is a simple, low-cost blood test for the early detection of colorectal
usecancer for global mass-market screening.
ersonalIP protection secured in all major international jurisdictions.
3
Investment Highlights
only | Disruptive and transformative technology |
Significantly cheaper and easier to administer | |
use | Globally addressable market |
ersonal | Performance better than market standard |
Manufacturing & Patents secured | |
Initial revenues targeted for 2022
Company Overview
Capital Structure | |||||
ASX Code | RHY | ||||
Share Price (at 9 November 2021) | $1.93 | ||||
Shares on Issue | 208.8 M | ||||
only | |||||
Unlisted Options | 16.8 M | ||||
Market Capitalisation | $403 M | ||||
Cash in bank (30 September 2021) | $7.7 M** | ||||
Top 20 Shareholders | 46% | ||||
use | |||||
Board and Management | |||||
Otto Buttula | Glenn Gilbert | ||||
Chairman | Chief Executive Officer | ||||
• Extensive financial, investment and biotech | • | Former Head of Global Sales, Marketing and | |||
experience. | BD at Medical Developments Int. (ASX: MVP). | ||||
• Co-Founder and CEO of IWL (ASX: IWL); | • | Various leadership positions at CSL (ASX: | |||
Founder / former CEO of Investors Mutual. | CSL). | ||||
• Formerly a Director of Imugene (ASX: IMU) | • | Strong Legal, IP & Operational management. | |||
and Chairman of Investorfirst, now HUB (ASX: | • | Broad international business experience. | |||
HUB). | |||||
• Chairman of HITIQ (ASX: HIQ), Non-Executive | |||||
Director of Oncosil Medical (ASX: OSL). | |||||
ersonal |
** Includes FY'21 R&D tax refund (see ASX Announcement 5 October 2021).
Share Price Chart
$7,000,000 | $2.50 | |||||||
$6,000,000 | ||||||||
$5,000,000 | $2.00 | |||||||
$4,000,000 | $1.50 | |||||||
$3,000,000 | $1.00 | |||||||
$2,000,000 | ||||||||
$1,000,000 | $0.50 | |||||||
$0 | $0.00 | |||||||
9-Mar-2016-Mar-2023-Mar-2030-Mar-206-Apr-2013-Apr-2020-Apr-2027-Apr-204-May-2011-May-2018-May-2025-May-201-Jun-208-Jun-2015-Jun-2022-Jun-2029-Jun-206-Jul-2013-Jul-2020-Jul-2027-Jul-203-Aug-2010-Aug-2017-Aug-2024-Aug-2031-Aug-207-Sep-2014-Sep-2021-Sep-2028-Sep-205-Oct-2012-Oct-2019-Oct-2026-Oct-202-Nov-209-Nov-2016-Nov-2023-Nov-2030-Nov-207-Dec-2014-Dec-2021-Dec-2028-Dec-204-Jan-2111-Jan-2118-Jan-2125-Jan-211-Feb-218-Feb-2115-Feb-2122-Feb-211-Mar-218-Mar-2115-Mar-2122-Mar-2129-Mar-215-Apr-2112-Apr-2119-Apr-2126-Apr-213-May-2110-May-2117-May-2124-May-2131-May-217-Jun-2114-Jun-2121-Jun-2128-Jun-215-Jul-2112-Jul-21 | 19-Jul-2126-Jul-212-Aug-219-Aug-2116-Aug-2123-Aug-2130-Aug-216-Sep-2113-Sep-2120-Sep-2127-Sep-214-Oct-2111-Oct-2118-Oct-2125-Oct-211-Nov-218-Nov-21 | |||||||
Volume | Share Price |
Trevor Lockett | Lou Panaccio | Eduardo Vom | ||
Executive-Director | Non-Executive Director | Non-Executive Director | ||
• Former Theme Leader Colorectal Cancer and | • | Chairman Avita Medical (ASX: AVH). | • | Co-Founder & Executive Director Planet |
Gut Health CSIRO. | • | Director Sonic Healthcare (ASX: SHL). | Innovation. | |
• Leader - Personalised Health Group CSIRO. | • | Chairman NeuralDX. | • | Director Atmo Biosciences. |
• Inventor on seven commercially-licensed | • Non-executive Director Unison Housing. | • Former VP Innovation, Genetic Technologies. | ||
patent families. | • | Former CEO Melb Pathology & Monash IVF. | • | Various senior leadership positions Vision |
BioSystems. |
5
This is an excerpt of the original content. To continue reading it, access the original document here.